Postural Orthostatic Tachycardia Syndrome (POTS) is a complex dysautonomia characterized by an abnormal increase in heart rate upon standing — typically ≥30 bpm — accompanied by symptoms including dizziness, fatigue, brain fog, and near-syncope. Many cases involve autoimmune dysfunction, small fiber neuropathy (SFN), chronic inflammation, and vascular dysregulation. MSC therapy targets several of these underlying mechanisms.
Why MSCs Are Relevant to POTS
Autonomic Nerve Repair
MSCs secrete BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor), which help repair and regenerate damaged autonomic nerve fibers. Small fiber neuropathy affecting autonomic nerves is increasingly recognized as a common finding in POTS, and MSCs' neuroprotective effects directly target this pathology.
Rebalancing the Sympathetic/Parasympathetic Axis
Many POTS patients experience excess sympathetic nervous system activity, leading to tachycardia and dizziness. MSCs may help modulate neurotransmitter levels and reduce neuroinflammation that perpetuates sympathetic overdrive, restoring equilibrium between sympathetic and parasympathetic functions.
Immune Regulation
Autoimmune POTS — where IgG autoantibodies target adrenergic or muscarinic receptors — is now a recognized subtype. MSCs suppress autoantibody-producing B-cells and expand regulatory T-cells, potentially reducing the autoimmune component driving autonomic dysfunction.
Vascular Function
Impaired peripheral vascular tone and reduced blood volume contribute to POTS symptoms. MSCs secrete VEGF, which improves vascular tone and microcirculation — addressing the circulatory component of dysautonomia.
Patient Selection
POTS patients with a clear autoimmune or inflammatory component (elevated inflammatory markers, known autoantibodies, concurrent autoimmune diagnoses, post-infectious onset) tend to be the best candidates. Hyperadrenergic POTS and neuropathic POTS subtypes are evaluated on a case-by-case basis. Your physician will assess your POTS subtype, current medications, and overall clinical picture on the evaluation call.